Last 24 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -45.77 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 39.06 | 124.79 | 91.98 | 2.10 | — | 6.34 | 2.15 | 13.49 | 9.28 | 24.91 | 53.08 | 90.42 | 130.99 | — | — | — | — | — | — | — | — |
| — | +1867.8% | +4185.1% | -84.4% | — | -74.5% | -96.0% | -85.1% | -92.9% | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | — | — | — | — | — | — | — | — | — | 73.88 | 10.52 | 11.51 | 6.52 | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | 14.74 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | 56.90 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | 75.68 | — | — | 56.60 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | — | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% |
| — | — | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | |
| Operating Margin | -36.5% | -544.4% | -386.9% | 3.0% | 271.5% | -254.6% | -4.3% | -770.4% | -604.1% | -1947.1% | -1716.9% | -2257.6% | -2057.5% | -1269.6% | -3664.6% | -1122.7% | -1204.4% | -630.0% | -731.6% | -627.3% | -493.8% |
| — | -113.8% | -8938.0% | +100.4% | +144.9% | +86.9% | +99.8% | +65.9% | +70.6% | -53.4% | +53.1% | -101.1% | -70.8% | -101.5% | -400.9% | -79.0% | -143.9% | -89.8% | -86.0% | -32.2% | -61.7% | |
| Net Margin | -80.8% | -941.2% | -618.2% | -20.2% | 280.7% | -235.5% | -35.2% | -853.3% | -890.2% | -1983.2% | -1248.7% | -2306.3% | -1483.6% | -1421.2% | -3759.7% | -1312.1% | -1249.5% | -612.4% | -758.4% | -647.7% | -490.8% |
| — | -299.7% | -1654.1% | +97.6% | +131.5% | +88.1% | +97.2% | +63.0% | +40.0% | -39.5% | +66.8% | -75.8% | -18.7% | -132.1% | -395.8% | -102.6% | -154.6% | -82.8% | -93.6% | -38.2% | -61.5% |
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | — | — | — | — | — | — | — | — | — | -184.4% | -48.6% | -54.4% | -53.9% | — | -286.8% | -136.8% | -76.2% | -33.1% | -37.3% | -50.4% | -52.3% |
| — | — | — | — | — | — | — | — | — | — | +83.0% | +60.2% | +29.2% | — | -669.4% | -171.2% | -45.8% | +30.0% | +20.4% | -75.6% | -172.2% | |
| ROA | -35.5% | -35.5% | -32.9% | -9.6% | -60.0% | -24.2% | -17.3% | -56.1% | -43.7% | -28.9% | -14.7% | -23.6% | -14.6% | -40.8% | -41.1% | -39.4% | -39.4% | -24.9% | -27.9% | -33.5% | -34.7% |
| — | -46.3% | -90.4% | +83.0% | -37.4% | +16.2% | -17.6% | -137.8% | -200.3% | +29.1% | +64.2% | +40.1% | +63.0% | -63.7% | -46.9% | -17.6% | -13.4% | +22.3% | +10.5% | -50.3% | -116.9% | |
| ROIC | — | — | — | — | — | — | — | — | — | — | — | — | -807.9% | -260.7% | -186.0% | -250.4% | -1166.3% | -383.5% | -315.8% | -254.4% | -196.7% |
| — | — | — | — | — | — | — | — | — | — | — | — | +30.7% | +32.0% | +41.1% | +1.6% | -492.8% | -158.5% | -57.5% | +27.3% | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q4 '25 | Q2 '25 | Q4 '24 | Q2 '24 | Q4 '23 | Q2 '23 | Q4 '22 | Q2 '22 | Q4 '21 | Q2 '21 | Q4 '20 | Q2 '20 | Q4 '19 | Q2 '19 | Q4 '18 | Q2 '18 | Q4 '17 | Q2 '17 | Q4 '16 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | — | — | — | — | — | — | — | — | — | 25.17 | 1.72 | 1.22 | 0.70 | — | — | 2.13 | 1.44 | 0.12 | 0.11 | 0.17 | 0.33 |
| — | — | — | — | — | — | — | — | — | — | — | -42.4% | -51.8% | — | — | +1172.5% | +342.3% | -16.4% | -63.5% | -14.7% | +325.1% | |
| Debt / EBITDA | — | — | — | 47.27 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 1.09 | 1.44 | 1.09 | 0.63 | 1.04 | 1.42 | 1.75 | 0.67 | 1.38 | 1.71 | 2.53 | 3.05 | 6.58 | 2.06 | 3.22 | 4.82 | 3.68 | 5.35 | 5.68 | 5.41 | 3.26 |
| — | +0.9% | -37.7% | -6.2% | -24.4% | -16.8% | -30.7% | -77.9% | -79.0% | -16.8% | -21.4% | -36.8% | +78.9% | -61.5% | -43.4% | -10.9% | +12.8% | +3.3% | +75.8% | -2.5% | -59.4% | |
| Quick Ratio | 1.09 | 1.44 | 1.09 | 0.63 | 1.04 | 1.42 | 1.75 | 0.67 | 1.30 | 1.68 | 2.53 | 2.86 | 6.58 | 1.88 | 3.03 | 4.68 | 3.58 | 6.21 | 5.68 | 6.42 | 3.26 |
| — | +0.9% | -37.7% | -6.2% | -19.9% | -15.1% | -30.7% | -76.4% | -80.2% | -10.6% | -16.6% | -39.0% | +83.6% | -69.8% | -46.7% | -27.0% | +9.9% | +23.5% | +85.5% | +2.5% | -58.8% | |
| Interest Coverage | -1.30 | -1.36 | -2.13 | 0.22 | — | — | 0.34 | -7.54 | -6.68 | — | — | — | — | -15.40 | — | -27.90 | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 24 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying NBTX stock.
Nanobiotix S.A.'s current P/E is -45.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Nanobiotix S.A.'s current operating margin is -36.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Nanobiotix S.A.'s business trajectory between earnings reports.